← All stocks

Inhibikase Therapeutics, Inc.

IKT Net buying
CIK 0001750149 #3494 in the set updated 18 Sep 2026
Bought (12 mo)
$3.00M
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
+$3.00M
+$3.00M against sales at will

By person

8 insiders · 2 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Sands Capital Life Sciences Pulse Fund II, L.P. entity
10% owner
$3.00M (1)
+$3.00M
13,018,965
$18.88M
+18.9%
RA CAPITAL MANAGEMENT, L.P. entity
10% owner
6,970,000
$10.11M
−72.1%
Bellini Roberto
Director
1,460,000
$2.12M
Cabell Christopher
President & Head of R&D
676,564
$981.02K
−33.3%
Aurentz Vincent
Director
510,596
$740.36K
−33.3%
Munshi Amit
Director
403,176
$584.61K
Kush Arvind
Director
145,000
$210.25K
BERMAN DENNIS N
Director
21,854
$31.69K

No percentages here. This company's share count has moved by a factor of 2.1 over the window, from 67,192,570 to 139,535,900 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
BERMAN DENNIS N
30 Jul 2026
Director
Exercised, kept
21,854
$1.26
$27.54K

What was left out

Form 4 filings counted 15
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 18,664,524
History held since 29 Dec 2020